EMFAT
VRDN icon

Emerald Mutual Fund Advisers Trust’s Viridian Therapeutics VRDN Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.27M Buy
+395,546
New +$6.37M 0.26% 109

Other funds holding VRDN

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
JSSH
J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FISPB
Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Emerald Mutual Fund Advisers Trust's VRDN Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 395,546 shares worth $7.27M. The stake represents 0.26% of the portfolio and ranks #109 among its holdings.

44 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust held 395,546 shares of Viridian Therapeutics worth $7.27M as of Q2 2026.
  • Viridian Therapeutics was a new Emerald Mutual Fund Advisers Trust position in Q2 2026.
  • Viridian Therapeutics made up 0.26% of Emerald Mutual Fund Advisers Trust's portfolio in Q2 2026, its #109 holding.
  • 44 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.